Obesity drugs that demonstrate benefits in cardiovascular disease, chronic kidney disease, sleep apnea, MASH, and metabolic syndrome may command stronger payer support and longer treatment duration
In addition, indirect evidence from a peripheral proteomic study of 2,000 obese individuals prescribed semaglutide showed that semaglutide downregulated tenascin-C (TNC) and upregulated progranulin (GRN), both of which may reduce AD-related pathology (139)
Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M
Analysis of acylcarnitines as their N-demethylated ester derivatives by gas chromatography-chemical ionization mass spectrometry
However, animal studies have demonstrated reproductive toxicity at high doses, and Vildagliptin is also excreted in milk